http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008088876-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_142204a88c5dd416a910c79ef38eb4b9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2008-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d39366e55c99bf91e5721f69f3271dc |
| publicationDate | 2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008088876-A3 |
| titleOfInvention | Tissue factor promoter polymorphisms |
| abstract | The invention provides compositions and methods for determining the likelihood of successful treatment with a pyrimidine based antimetabolite chemotherapy drug such as 5- fluorouracil or in combination with a platinum based chemotherapy drug, such as 5- fluorouracil/oxaliplatin. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy. |
| priorityDate | 2007-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.